

# Once-daily dosing and administration with AZSTARYS™

Available in 3 dosage strengths to meet the individual needs of your patients<sup>1</sup>



The capsules are the same size across the 3 dosage strengths—slightly smaller than a dime.

Graphic is for comparative purposes only. Not actual size.

## 3 flexible administration options for the morning routine<sup>1</sup>



## AZSTARYS may be taken with or without food<sup>1</sup>

<sup>a</sup>The capsule contents may be sprinkled into 2 oz (50 mL) of water or 2 tablespoons of applesauce. The mixture should be consumed within 10 minutes and cannot be stored for future use.

## INDICATION

AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

## IMPORTANT SAFETY INFORMATION

### WARNING: ABUSE AND DEPENDENCE

- CNS stimulants, including AZSTARYS, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy

  
azstar<sup>ys</sup>™ II  
serdexmethylphenidate  
and dexmethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules



Please see additional Important Safety Information on next page and [click here](#) or scan the QR code for Full Prescribing Information, including Boxed WARNING.


# Dose optimization with AZSTARYS

In a clinical study of patients with ADHD aged 6 to 12 years, most patients were optimized on higher doses<sup>1,2</sup>

At the end of the dose-optimization phase<sup>2</sup>

## 93.5%

of patients were optimized to the 2 higher doses of AZSTARYS



AE, adverse event.

<sup>a</sup>The percentage of patients optimized does not add to 100% because 5 patients dropped out of the dose-optimization phase (4 due to AEs and 1 failed to meet randomization criteria). The percentages here are calculated based on a total population of 155 patients.<sup>2</sup>

## IMPORTANT SAFETY INFORMATION (continued)

### Contraindications

- Known hypersensitivity to serdexmethylphenidate, methylphenidate, or other product components. Bronchospasm, rash, and pruritus have occurred with AZSTARYS. Hypersensitivity reactions such as angioedema and anaphylactic reactions have occurred with other methylphenidate products.
- Concomitant treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days, because of the risk of hypertensive crisis.

### Warnings and Precautions

- Sudden death has been reported in association with CNS stimulant treatment at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems. In adults, sudden death, stroke, and myocardial infarction have been reported at recommended doses. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias, coronary artery disease, or other serious heart problems.

Please see additional Important Safety Information on next page and [click here](#) for Full Prescribing Information, including Boxed WARNING.

## Clinical study design<sup>1,2</sup>

- The randomized, double-blind, placebo-controlled, parallel-group, analog classroom study included pediatric patients with ADHD aged 6 to 12 years (mean, 9 years)
- During the open-label dose-optimization phase (3 weeks), 155 patients were started on AZSTARYS 39.2 mg/7.8 mg once daily in the morning
- The dose could be titrated weekly to 26.1 mg/5.2 mg, 39.2 mg/7.8 mg, or 52.3 mg/10.4 mg (maximum dose) based on tolerability and best individual response in the opinion of the investigator

Approximately 60% of patients had no prior use of ADHD medications<sup>2</sup>

## IMPORTANT SAFETY INFORMATION (continued)

### Warnings and Precautions (continued)

- CNS stimulants cause an increase in blood pressure and heart rate. Monitor all patients for hypertension and tachycardia.
- *Exacerbation of Pre-existing Psychosis:* May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. *Induction of a Manic Episode in Patients with Bipolar Disorder:* May induce a mixed/ manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, or depression). *New Psychotic or Manic Symptoms:* At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a history of psychotic illness or mania. Discontinue if symptoms occur.

Please see additional Important Safety Information on next page and [click here](#) for Full Prescribing Information, including Boxed WARNING.



serdexmethylphenidate  
and dexmethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules



# CoriumCares offers support for patients prescribed AZSTARYS



## Eligible patients may pay as little as **\$0** for their first prescription<sup>a</sup>

Patients may pay as little as

**\$50**

for refills if their insurance covers AZSTARYS.

Patients may pay as little as

**\$75**

for refills if their insurance does not cover AZSTARYS.

### There are 3 ways to help eligible patients access the support they need

1



Patients can register for copay savings at [AZSTARYS.com](https://www.AZSTARYS.com).

2

Patients or their caregivers can call **1-800-910-8432** for information about CoriumCares support, such as

- Resources for patients starting treatment
- Assistance with prior authorization and other access resources
- Ongoing call center support for questions

3

Give your patients and their caregivers the **Welcome Kit** provided by Corium so they have all the information they need when starting AZSTARYS.

<sup>a</sup>Restrictions and a maximum benefit may apply. See Terms and Conditions at [AZSTARYS.com](https://www.AZSTARYS.com).




serdexmethylphenidate  
and dexmethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules

Please see Important Safety Information on next page and [click here](#) for Full Prescribing Information, including Boxed WARNING.

# Starting patients on AZSTARYS<sup>1</sup>

If switching from another treatment, discontinue that treatment and titrate with AZSTARYS using the titration schedule below.



## Switching from other MPH products

Do not substitute AZSTARYS for other MPH products on a milligram-per-milligram basis because these products have different PK profiles from AZSTARYS and may have different MPH base composition.

[Visit AZSTARYS-pro.com to learn more](https://www.a-zstar-ys.com)

MPH, methylphenidate; PK, pharmacokinetic.

## IMPORTANT SAFETY INFORMATION (continued)

### Drug Interactions

- Adjust dosage of antihypertensive drug as needed. Monitor blood pressure.
- Avoid use of AZSTARYS on the day of surgery if halogenated anesthetics will be used.

Please see additional Important Safety Information on previous pages and [click here](#) for Full Prescribing Information, including Boxed WARNING.

**References:** **1.** AZSTARYS. Prescribing information. Corium Inc; 2021. **2.** Data on file; Corium Inc.

**Corium**

© 2021 Corium Inc. All Rights Reserved.  
COM-AZS-001450 09/21

  
**azstar**ys™ 

serdexmethylphenidate  
and dexmethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules